First Read China Healthcare NRDL/CIDL 2026 prelim form review: high pass rate, broad participation

Research evidence excerpt

First Read China Healthcare NRDL/CIDL 2026 prelim form review: high pass rate, broad participation

Global Research

29 June 2026ab

First Read

EquitiesChina Healthcare

NRDL/CIDL 2026 prelim form review: high pass China

rate, broad participation Healthcare

Chen Chen, PhD

Analyst

chen-zb.chen@ubs.com

Generally high pass rate of the preliminary form review +86-10-5832 8201

On 29 June, the National Healthcare Security Administration (NHSA) announced the Anita Wei

preliminary form view results for the 2026 NRDL (national reimbursement drug list) and Analyst

CIDL (commercial innovative drug list) adjustments. A total of 611 drugs have passed anita.wei@ubs.com

out of 818 application files (+100 YoY) about 674 drugs (+41 YoY), including 557 for +852-2971 7459

NRDL and 54 drugs for CIDL. The NHSA mentioned that the overall pass rate is high at Liz Han, CFA

c.92% (up 8ppt YoY, excluding pre-applications), and for the first time it included 50 Analyst

new drugs and 11 new indications for pre-application before the arrival of their final liz.han@ubs.com

approvals. According to the NHSA, the public comments will be solicited June 29 - July 5 +852-2971 6106

to determine the participants, with the final negotiation results to be released end Nov. David Guo, PhD

More GLP-1s and ADCs; new radio, Alzheimer's and insomnia drugs S1460524040001

Among entrants, we highlight: 1) four more GLP-1s, such as orforglipron and david-za.guo@ubs.com

+86-10-5832 8010mazdutide, are NRDL new attenders; 2) five new ADCs (including iza-bren) are new

attenders for NRDL, and one for CIDL; 3) despite three new CAR-Ts applied for NRDL,

the NHSA mentioned that final negotiation may still comprehensively consider the

affordability and efficacy; 4) radiopharmaceuticals such as Sinotau's florbetaben [18F]